The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

North America held the largest kidney cancer drugs market share, and Middle East was the fastest-growing region in 2022.

The global kidney cancer drugs market is expected to grow from $7.41 billion in 2022 to $7.81 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The global kidney cancer drugs market size is expected to grow to $9.33 billion in 2027 at a CAGR of 4.5%.

Major Driver In The Kidney Cancer Drugs Market ­– Rise In The Incidence Of Renal Cancer
According to the American Cancer Society, a US-based health organisation dedicated to cancer eradication, there will be 79,000 new cases of kidney cancer diagnosed in January 2022 (50,290 men and 28,710 women), and 13,920 people will die from the disease (8,960 men and 4,960 women). The majority of patients are diagnosed between the ages of 65 and 74, with a diagnostic age of 64 being the norm. Kidney cancer is extremely rare in people under the age of 45. As a result, the kidney cancer drug market is expanding.

View More On The Kidney Cancer Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Key Kidney Cancer Drugs Market Segments
1) By Type: Renal Cell Carcinoma, Urothelial Carcinoma, Others (Renal Sarcoma, Renal Lymphoma)
2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Other Products
3) By End Users: Hospitals, Clinics, Research Center, Other End-Users

Recent Kidney Cancer Drugs Market Trend – Adopting Combination Therapy
Combination therapy combines the effects of multiple medications, lowering the chances of cancer-resistant cells forming. The discovery of combination therapy has resulted from a better understanding of the origins and effects of kidney cancer. The medications from vascular endothelial growth factor (VEGF), which activate the protein in the blood, are combined with inhibitors of the mammalian target of rapamycin (mTOR), which promotes cellular biogenesis, in this treatment. Merck & Co., Inc., a US-based research-oriented biopharmaceutical company, announced in November 2021 that its anti-PD-1 drug KEYTRUDA has received FDA approval for the adjuvant treatment of renal cell carcinoma (RCC) patients who are at intermediate-high or high risk of recurrence after nephrectomy or after nephrectomy with resection of metastatic lesions.

Kidney Cancer Drugs Market Prominent Players
Major players in the kidney cancer drugs market are Bayer AG, Pfizer Inc., Novartis International AG, Exelixis Inc., F. Hoffmann-La Roche Ag, Genentech Inc., Glaxosmithkline PLC., Active Biotech, Amgen, Thermo Fisher Scientific Inc., Bristol-Myers Squibb, Eisai, Roche, Cipla Limited, Onyx, Abbott Laboratories, Aveo Pharmaceuticals, Immatics Biotechnologies, Prometheus Laboratories, Argos Therapeutics, Myriad Genetics Inc., NeoGenomics Laboratories, NanoString Technologies Inc., Sysmex Corporation, Rosetta Genomics, Illumina Inc. and Quest Diagnostics Incorporated.

Request A Sample Of The Global Kidney Cancer Drugs Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp

The Kidney Cancer Drugs Global Market Report 2023  provides a comprehensive overview on the kidney cancer drugs market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the kidney cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Kidney cancer medications that can be used to treat the disease. These therapies are known as systemic therapy because they can reach cancer cells virtually anywhere in the body. Depending on the type of kidney cancer, a variety of drugs may be employed. It works by inhibiting tyrosine kinases, which are important proteins in cancer cells that aid in growth and survival, as well as angiogenesis, the formation of new blood arteries that feed malignancies.

View More Related Reports –
Cancer Biologics Global Market Report 2023
Cancer Diagnostics Global Market Report 2023
Cancer Biomarker Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model